http://orcid.org/0000-0002-3347-956X
References
- Duan MH, Li H, Cai H. A rare e13a3 (b2a3) BCR-ABL1 fusion transcript with normal karyotype in chronic myeloid leukemia: the challenges in diagnosis and monitoring minimal residual disease (MRD). Leukemia Res. 2017;59:8–11.
- Haigh S, Cuthbert G. Fluorescence in situ hybridization characterization of different cryptic BCR-ABL rearrangements in chronic myeloid leukemia. Cancer Genet Cytogenet. 2004;155:132–137.
- Brahmbhatt MM, Trivedi PJ, Patel DM, et al. Location of the BCR/ABL fusion genes on both chromosomes 9 and 22 in Ph negative young CML patients: an Indian experience. Indian J Hematol Blood Transfus. 2014;30:241–246.
- Luatti S, Baldazzi C, Marzocchi G, et al. Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: molecular cytogenetic characterization and influence on TKIs therapy. Oncotarget. 2017;8:29906–29913.
- Batista DAS, Hawkins A, Murphy FM, et al. BCR/ABL rearrangement in two cases of Philadelphia chromosome negative chronic myeloid leukemia: deletion on the derivative chromosome 9 may or not be present. Cancer Genet Cytogenet. 2005;163:164–167.
- Fugazza G, Garuti A, Marchelli S, et al. Masked Philadelphia chromosome due to atypical BCR/ABL location on the 9q34band and duplication of the der(9) in a case of chronic myelogenous leukemia. Cancer Genet Cytogenet. 2005;163:173–175.
- Bennour A, Bellâaj H, Ben Youssef Y, et al. Molecular cytogenetic characterization of Philadelphia-negative rearrangements in chronic myeloid leukemia patients. J Cancer Res Clin Oncol. 2011;137:1329–1336.
- Hochhaus A, Mahon FX, Le Coutre P, et al. Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase: ENEST1st sub-analysis. J Cancer Res Clin Oncol. 2017;143:1225–1233.
- Baccarani M, Deininger MW, Rosti G, et al. European Leukemia Net recommendations for the management of chronic myeloid leukemia. Blood. 2013;122:872–884.
- Luatti S, Castagnetti F, Marzocchi G, et al. Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML Analysis. Blood. 2012;120:761–767.
- Fischer K, Fröhling S, Scherer SW, et al. Molecular cytogenetic delineation of deletions and translocations involving chromosome band 7q22 in myeloid leukemias. Blood. 1997;89:2036–2041.
- De Melo VA, Milojkovic D, Marin D, et al. Deletions adjacent to BCR and ABL1 breakpoints occur in a substantial minority of chronic myeloid leukemia patients with masked Philadelphia rearrangements. Cancer Genet Cytogenet. 2008;182:111–115.
- Castagnetti F, Testoni N, Luatti S, et al. Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA CML Working Party analysis. J Clin Oncol. 2010;28:2748–2754.